Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors
Alexandra E Gould1, Ruth Adams, Sharmila Adhikari
1Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States. sandy.gould@mpi.com
Abstract:
Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.
Insights
Targeting the Raf pathway, specifically B-Raf, shows promise for melanoma treatment. New tetrahydronaphthalene compounds effectively inhibit B-Raf mutant signaling and reduce tumor growth in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutant B-Raf signaling drives tumor growth, particularly in melanoma.
- Inhibiting B-Raf or its substrate MEK is a validated preclinical strategy.
- Recent clinical trials show promise for B-Raf inhibitors in melanoma patients.
Purpose of the Study:
- To design and optimize novel tetrahydronaphthalene-derived compounds.
- To evaluate these compounds as potent inhibitors of the Raf pathway.
- To assess their efficacy in preclinical cancer models.
Main Methods:
- Medicinal chemistry for compound design and optimization.
- In vitro assays to assess Raf pathway inhibition.
- In vivo studies using mouse xenograft models to evaluate tumor growth inhibition.
- Pharmacokinetic profiling in rodent models.
Main Results:
- Tetrahydronaphthalene derivatives were successfully designed and optimized.
- Compounds demonstrated potent inhibition of the Raf pathway in vitro.
- These compounds exhibited favorable pharmacokinetic properties in rodents.
- Significant inhibition of B-Raf mutant tumor growth was observed in vivo.
Conclusions:
- Tetrahydronaphthalene-derived compounds are potent inhibitors of the Raf pathway.
- These novel compounds show therapeutic potential for B-Raf mutant cancers.
- Further development of these inhibitors is warranted for melanoma treatment.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
